socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M Anaptys priced its IPO on Wednesday night at $15.00 AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. READ MORE>>.

Avalon 100

Avalon San Diego Pricing Invest 100

socalTECH

MAY 7, 2015

San Diego-based biotech developer aTyr Pharma is debuting in its IPO this morning, after pricing its IPO at $14.00 the company will trade as LIFE on the NASDAQ Global Market starting this morning. per share last night. The company raised $75M in the offering.

San Diego 100

San Diego Pricing Invest Marketing 100

Xconomy

OCTOBER 27, 2016

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says.

Venture Capital 40

Venture Capital Pricing Invest Report 40

TechCrunch LA

DECEMBER 8, 2020

He did note that in the four markets where the company has gone live since launching its business in January 2019 — San Diego, Los Angeles, the Inland Empire , and Sacramento — has yielded an annualized revenue run rate of over $400 million in gross merchandise value (the total value of home sales transacted on its platform).

Sales 282

Sales Demand San Diego Funding 282

socalTECH

JANUARY 20, 2015

San Diego-based biopharmaceuticals developer Tracon Pharmaceuticals said in a regulatory filing today that it is estimated its IPO pricing at between $12.00 The company--which filed for an IPO over the holidays--is looking to raised $57.96M on the NASDAQ Global Market as TCON. and $14.00 READ MORE>>.

San Diego 100

San Diego Acquisition Pricing Invest 100

Xconomy

SEPTEMBER 6, 2019

Being first to market with a new type of drug brings advantages. It grabs market share that followers have to steal away. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. But the first mover isn’t infallible if someone else has something better.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

APRIL 13, 2017

Tocagen raised $85 million in its stock market debut today, and underwriters saw enough demand to increase the number of shares in the initial public offering. San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 million shares priced between $10 to $12 each. million shares at $10 per share.

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

JANUARY 29, 2019

The New York-based startup said Tuesday that the new funding round, which is being led by Goldman Sachs Private Capital Investing group, brings its total investment to $35 million. Billie, a monthly subscription service for shaving and body care products for women, has raised $25 million.

Product 90

Product Services Invest Pricing 90

Xconomy

MAY 9, 2019

It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming.

Pricing 110

Pricing Research Capital Marketing 110

Xconomy

JUNE 3, 2019

Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too. The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010.

Funding 79

Funding Pricing Invest Develop 79

Xconomy

MAY 17, 2019

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. But such tools only work when companies play fair.

Pricing 79

Pricing Competition Tool Marketing 79

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. If approved this week or next, it would be just the second gene therapy to come to market in the US. healthcare system must.

Pricing 86

Pricing Marketing Develop Development 86

socalTECH

APRIL 26, 2017

Eugene Cho is CEO of San Diego-based Echo Laboratories (www.discover-echo.com), a startup which is developing a new kind of microscope. We've created an alternative, a hybrid microscope for the price of one. I saw the market opportunity, and after being in the industry for fourteen years, thought: what can we do next?

Tech Coast Angels 124

Tech Coast Angels Startup Sales Slides 124

Xconomy

JULY 18, 2019

Initial public offerings took a brief summer break the week of Independence Day, but healthcare IPO activity resumed this week as three more companies joined the US public markets. Here’s a recap of the biotech companies that priced IPOs Wednesday evening. Read more » Reprints | Share:

Organization 77

Organization Pricing Activity Marketing 77

Xconomy

AUGUST 30, 2016

Petco, the privately held pet supplies company based in San Diego, said today it led a $10 million Series A financing in Los Angeles-based Petnet, a three-year-old startup developing technology-enabled pet feeders and pet food delivery service. The deal also reflects Petco’s expanding interests in technology following the company’s $4.6-billion

San Diego 52

San Diego Los Angeles Mobile Equity 52

socalTECH

JUNE 3, 2013

There''s been a subtle--but very significant shift--in the solar power market in recent years, particularly in California, where it''s actually cheaper in many cases to lease solar panels on your roof, than to pay the power company. That''s in part because of a significant investment in China around solar manufacturing.

Equity 234

Equity Invest Marketing Product 234

socalTECH

APRIL 26, 2017

Eugene Cho is CEO of San Diego-based Echo (www.discover-echo.com), a startup which is developing a new kind of microscope. We've created an alternative, a hybrid microscope for the price of one. I saw the market opportunity, and after being in the industry for fourteen years, thought: what can we do next?

Tech Coast Angels 100

Tech Coast Angels Startup Sales Slides 100

Xconomy

JULY 25, 2019

Castle Biosciences is joining the public markets through a $64 million IPO that will support cancer tests that help doctors make treatment decisions. On Wednesday evening, Castle priced its offering of 4 million shares at $16 apiece, which was the high end of its targeted price range.

Training 60

Training Pricing Activity Help 60

Xconomy

MAY 22, 2020

COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies.

Company 145

Company Companies Marketing Develop 145

Xconomy

MAY 2, 2019

Beyond Meat priced its IPO Wednesday evening at $25 per share, which was the high end of its revised range. million shares at that price. The food technology company’s upsized IPO has raised $241 million to finance plans to bring its plant-based “meat” to more grocery stores and restaurants across the country.

El Segundo 82

El Segundo Pricing Technology Venture Capital 82

Xconomy

JULY 20, 2016

draws closer, more gene therapy players are entering the public markets. Today, it’s San Francisco’s Audentes Therapeutics, which aims to use gene therapy to treat a group of rare diseases. If approved by the FDA, it would become the first ever marketed gene therapy in the U.S.

Pricing 40

Pricing Equity Marketing Tool 40

Xconomy

APRIL 6, 2018

They will try to shepherd to market a different type of the promising cancer immunotherapy: allogeneic T cells that come from donors, not from a patient’s own blood. There were plenty of policy and drug-price headlines, Read more » Reprints | Share: After the deals, we’ll move on to data.

Study 55

Study Pricing Conference Marketing 55

Xconomy

JUNE 21, 2018

The first was Eidos Therapeutics (NASDAQ: EIDX ), which raised $106 million in its stock market debut. The San Francisco company priced its IPO late Tuesday, selling 6.25 The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours.

Study 72

Study Startup Pricing Funding 72

Both Sides of the Table

JUNE 3, 2010

And the broader question of whether VC’s will continue to invest in the Twitter ecosystem. Discussion: Had a long chat about PicClick , a company founded by Ryan Sit in San Diego. Pricing engine helps publishers ascertain ad inventory pricing by analyzing ad transaction data from the market/exchanges.

Venture Capital 214

Venture Capital Startup Design S3 214

socalTECH

FEBRUARY 16, 2010

For this morning's interview, we talked with Noah Auerhahn , President of San Diego-based Extrabux (www.extrabux.com), an online site focused on providing consumers with comparison shopping combined with discount offers. We think we've really gotten the product validated by the market, particularly with Cyber Monday.

USC 207

USC CPC Sites Startup 207

Both Sides of the Table

APRIL 28, 2010

Rustic Canyon is an LA-based, but geography-agnostic VC that is currently investing from a $200 million fund. They were originally founded inside of Times Mirror and had a huge string of major investment success before spinning out as a fully independent fund. It is a platform to help brands building viral marketing campaigns.

Venture Capital 270

Venture Capital Capital Rustic Canyon Mobile 270

Xconomy

JULY 21, 2016

After a year in which Biogen’s share price has fallen by more than a third and one of its top drug prospects failed, Scangos, who has led the company since 2010, has announced plans to step down. In May, Biogen even announced plans to spin off its hemophilia business —which includes two marketed drugs for the blood disease—into a new company.

San Diego 40

San Diego Conference Pricing Acquisition 40

Xconomy

AUGUST 5, 2016

Just as many M&A rumors flame out as lead to deals, of course, but the news was enough to give Biogen’s stock price a big bump, and ignite chatter about what a sale of one of biotech’s heavyweights would mean, particularly for the Boston area. The rumors boosted Biogen’s sinking stock price nearly 10 percent.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Both Sides of the Table

JANUARY 1, 2016

We want to invest in early-stage technology enabled startup businesses – upfront in the funding cycle. In fact, 90% of our investments are either Seed or A-round investments (10% are B-round). We’re a national venture capital investment firm but with our roots firmly in Los Angeles. That’s healthy.

Startup 150

Startup Coach Course Invest 150

socalTECH

AUGUST 6, 2009

Last month, San Diego-based Advanced Telemetry (www.advancedtelemetry.com) announced that the company had scored a Series B round of funding from clean technology investor Quercus Trust and 21Ventures, for the firm's energy monitoring solutions. It's a well established market, and those are sold to large industrial customers.

Startup 100

Startup Customer Custom Outsource Development 100

Xconomy

MAY 31, 2019

Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from Oklahoma. [ Corrected 5/31/19, 8:48 am ET. This week, a trial began litigating Johnson & Johnson’s responsibility for opioid addiction in the Sooner State.

Marketing 67

Marketing San Diego Company Companies 67

socalTECH

NOVEMBER 10, 2010

For today's interview, we talked with San Diego-based ShowUHow (www.showuhow.com), a firm which is providing both content and a software platform which allows e-commerce retailers to provide video instruction guides on the products they carry. Manufacturers have quite a bit of pressure from the top end in pricing.

Guide 113

Guide Training Platform Product 113

Xconomy

JULY 19, 2016

In 2015, Cybersecurity startups saw 332 funding deals with investments hitting the highest ever at $3.8 In general, M&A is a natural part of the IT security market. It’s why this market segment is so attractive to venture investors. billion (235 percent growth over 5 years). What we’ve also seen is the increase in M&A.

Symantec 40

Symantec IBM IBM Acquisition 40

Xconomy

OCTOBER 24, 2016

Today, there’s no need to invest that much effort when cheap connected devices are ubiquitous. Even if they could be field upgraded, why would the manufacturer invest in a security patch? They already got paid for those devices; investing in them would only further squeeze their minuscule margins. One Target, Many Victims.

Netflix 40

Netflix Services Outsource Development Outsource 40

Xconomy

SEPTEMBER 23, 2016

Another biopharma executive went before Congress to explain drug price hikes. Taking heat over the EpiPen scandal, she tried to stick to her script , getting testy when legislators brought up a USA Today story about her mother helping market the life-saving anti-allergy injection to schools.

Research 40

Research Technical Review Startup Develop 40

Xconomy

AUGUST 12, 2016

And Pfizer’s is already on the market, and generated $514 million in the last quarter alone. —This week’s gene therapy news: MIT Technology Review reported that Strimvelis, the gene therapy recently approved in Europe and given a $665,000 price tag, has a money-back guarantee if it doesn’t work. In the U.S., In the U.S.,

Google 40

Google Technical Review News Research 40